Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Safety Clinical Trial of Peanut Allergy Vaccine (Polyvac Peanut, VLP-Based Peanut Product)

Next Previous
Trial Profile

A Phase I Safety Clinical Trial of Peanut Allergy Vaccine (Polyvac Peanut, VLP-Based Peanut Product)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peanut allergy VLP Vaccine Allergy Therapeutics (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; First in man
  • Acronyms PROTECT
  • Sponsors Allergy Therapeutics

    • Most Recent Events

    • 26 Jan 2022 According to an Allergy Therapeutics media release, topline data from this Phase I PROTECT trial in adult patients is expected in H1 2023, earlier than the originally intended data readout of Q4 2023.
    • 26 Jan 2022 According to an Allergy Therapeutics media release, the United States Food & Drug Administration (FDA) has cleared the Groups Investigational New Drug application (IND) for Peanut-allergy-VLP-Vaccine to initiate this trial
    • 23 Sep 2021 According to an Allergy Therapeutics media release, expected to start of this trial in 2022 and expected to read out in H2 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top